Ginkgo Bioworks Holdings (DNA) Receivables - Net (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Receivables - Net came in at $454000.0 in Q1 2026, down 98.27% YoY from $26.3 million in Q1 2025, and down 98.11% on a QoQ basis from $24.0 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Receivables - Net (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Receivables - Net data on file, last reported at $454000.0 in Q1 2026.
- Quarterly Receivables - Net fell 98.27% year-over-year to $454000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $454000.0 (down 98.27% YoY) and the FY2025 annual result came in at $24.0 million, up 4000.0% from the prior year.
- Receivables - Net fell to $454000.0 in Q1 2026, from $24.0 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $171.6 million in Q2 2022 to a low of $302000.0 in Q2 2024.
- A 5-year average of $38.8 million and a median of $21.4 million in 2025 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2023 — Receivables - Net slumped 99.48% — and 2025, when it jumped 7235.1%.
- Tracing DNA's Receivables - Net over 5 years: stood at $1.6 million in 2022, then plunged by 52.37% to $742000.0 in 2023, then retreated by 21.02% to $586000.0 in 2024, then surged by 4000.0% to $24.0 million in 2025, then sank by 98.11% to $454000.0 in 2026.
- The last three Receivables - Net figures came in at $454000.0 (Q1 2026), $24.0 million (Q4 2025), and $21.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.01 Mn |
| Jun 30, 2026 | 13.01 Mn |
| Mar 31, 2026 | 454,000.00 |
| Mar 31, 2026 | 454,000.00 |
| Dec 31, 2025 | 24.03 Mn |
| Dec 31, 2025 | 24.03 Mn |
| Sep 30, 2025 | 21.43 Mn |
| Sep 30, 2025 | 21.43 Mn |
| Jun 30, 2025 | 22.15 Mn |
| Jun 30, 2025 | 22.15 Mn |
| Mar 31, 2025 | 26.29 Mn |
| Mar 31, 2025 | 26.29 Mn |
| Dec 31, 2024 | 586,000.00 |
| Dec 31, 2024 | 586,000.00 |
| Sep 30, 2024 | 531,000.00 |
| Sep 30, 2024 | 531,000.00 |
| Jun 30, 2024 | 302,000.00 |
| Jun 30, 2024 | 302,000.00 |
| Mar 31, 2024 | 24.19 Mn |
| Mar 31, 2024 | 24.19 Mn |